Meningitis Vaccines Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Meningitis Vaccines Market is segmented By Vaccine Type (Meningococcal Conjugate Vaccine, Serogroup B Meningococcal Vaccine, Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine, Hemophilus Influenzae Type B (Hib) Vaccine), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Meningitis Vaccines Market Size

The global meningitis vaccines market reached USD million in 2023 and is projected to witness lucrative growth by reaching up to USD million by 2031. The market is growing at a CAGR of 9.6% during the forecast period (2024-2031).  Meningitis is  inflammation of the meninges, the lining of the brain, and the spinal cord.

It is most commonly caused by bacterial, viral, or fungal infections. Symptoms progress rapidly and rapidly deteriorate a person's health. Viral infections are  rarely life threatening. Most people recover without noticeable sequelae, but for some  it can lead to long-term, life-changing illness. Severe cases of meningitis are most often caused by bacterial infections. Vaccination of the most at-risk populations develops protection against some of the most common causes of  disease and provides a safe way to reduce the risk of spreading infection within communities

Meningitis Vaccines Market Scope

For More Insights Request Free Sample

Meningitis Vaccines Market Dynamics

The increasing FDA approvals for the vaccine by the key market players are the factors to drive the market growth.

On October 17, 2022, GSK plc announced that the US Food and Drug Administration (FDA) approved a new presentation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W. The Menveo one-vial presentation now comes in a ready-to-use single vial giving healthcare providers a more convenient option. The Menveo one-vial presentation will initially be available to US federal customers, with broader availability anticipated in mid-2023.

Additionally, On December 29, 2022, Pfizer PFE announced that the FDA has accepted its biologics license application (BLA) for its pentavalent meningococcal vaccine candidate (MenABCWY). The BLA seeks approval of MenABCWY for the prevention of meningococcal disease caused by the five meningococcal serogroups that cause the majority of invasive meningococcal disease: serogroups A, B, C, W, and Y. As a result of the aforementioned factors, the market is expected to drive during the forecast period.

The high cost and side effects of vaccines are factors hindering the market growth.

According to the Pan American Health Organization, healthcare costs for meningococcal disease range from $4,500 to $6,500 per patient, with outbreak control costs exceeding $3 million (USD) in some areas. In addition, meningococcal vaccination can rarely cause severe allergic reactions. Hoarseness, wheezing, and trouble breathing or swallowing are all symptoms. Therefore, the above factors are expected to hamper the market during the forecast period. 

Meningitis Vaccines Market Segment Analysis

The global meningitis vaccines market is segmented based on vaccine, age group, end user, distribution channel and region.

The pneumococcal vaccines segment will be dominated by market players due to its benefits, product launches, and clinical trials during the forecast period.

Pneumococcal infection is a disease caused by Streptococcus pneumoniae bacteria. Vaccines help prevent pneumococcal infections. Two pneumococcal vaccines are available in the United States. Pneumococcal conjugate vaccine (PCV13, PCV15, PCV20) and pneumococcal polysaccharide vaccine (PPSV23). For instance, Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) from Pfizer is approved for active immunization in adults 18 years of age and older to prevent pneumonia and invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Prevnar 20 is approved under accelerated approval to prevent pneumonia caused by S. pneumoniae serotypes 8, 10, 11A, 12F, 15B, 22F, and 33F. Furthermore, the increasing clinical trials and product launches by the market players are the factors to drive the market in the forecast period. For instance, On August 12, 2022, Pfizer Inc. announced positive top-line results from its pivotal U.S. Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population. Above mentioned factors help the product segment to dominate the market.

Source: DataM Intelligence Analysis (2023)

Meningitis Vaccines Market Geographical Share

Rising awareness of pneumococcal vaccines, project launches, and clinical trials in the region are the factors to drive regional growth.

North America region accounted for the largest market share in the forecast period. The regional growth is driven by rising awareness of pneumococcal vaccines, project launches, and clinical trials. For instance, the Meningitis B Action Project is a joint initiative by the Kimberly Coffey Foundation and The Emily Stillman Foundation. On January 26, 2023, the Meningitis B Action Project launched the Meningitis B Action Project Dinner Club. The Dinner Club is intended to foster open discussion about the barriers to meningococcal meningitis prevention and how the projects can work together to overcome those obstacles. The Meningitis B Action Project Dinner Club's first stop was Salt Lake City, Utah. Furthermore, the above-stated factors depict the North American region's dominance globally.

Source: DataM Intelligence Analysis (2023)

Meningitis Vaccines Companies

The major global players include GlaxoSmithKline plc., Sanofi S.A., Merck & Co., Inc., Pfizer Inc., Novartis AG, Walvax Biotechnology Co., Ltd., Incepta Pharmaceuticals Ltd., Serum Institute of India Pvt. Ltd., Vacsera, Zhi Fei Biological, BIO MED, CanSinoBIO and Eubiologics Co., Ltd.

Key Developments

• On 16 June 2021, Te Pātaka Whaioranga – Pharmac announced a decision to fund the meningococcal B vaccine (Bexsero) for people who are in close contact with meningococcal cases or who are at higher risk of meningococcal disease, from 1 July 2021. Vaccination will be funded for people who are in close contact with meningococcal cases of any meningococcal group (e.g. A, C, W, Y, or B), at higher risk of meningococcal B disease because they are pre- or post-splenectomy, have functional or anatomic asplenia, have HIV, have complement deficiency, are pre- or post-solid organ transplant, are post-bone marrow transplant, are pre- or post-immunosuppression.
• On April 24, 2020, The U.S. Food and Drug Administration (FDA) approved a Biologics License Application for MenQuadfi Meningococcal (Groups A, C, Y, W) Conjugate Vaccine for the prevention of invasive meningococcal disease in persons 2 years of age and older.
• On September 15, 2022, Pfizer Inc. announced positive top-line results from the pivotal Phase 3 trial (NCT04440163) assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints, with the investigational vaccine demonstrating non-inferiority to licensed vaccines for the five meningococcal serogroups that cause the majority of invasive meningococcal disease: serogroups A, B, C, W, and Y.1 Currently, MenACWY and MenB vaccines are licensed separately, and no single vaccine is available to help protect against the five serogroups.

Why Purchase the Report?

• To visualize the global meningitis vaccines market segmentation based on the vaccine, age group, end user, distribution channel and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of meningitis vaccines market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global meningitis vaccines market report would provide approximately 92 tables, 108 figures and 195 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies